TGTX climbs on upbeat subcutaneous BRIUMVI data and expanded development plans

TG Therapeutics (TGTX) is up 7.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to fresh clinical updates for BRIUMVI, including positive topline Phase 1 data for a subcutaneous formulation in myasthenia gravis and the start of an additional trial that could broaden the product’s long-term opportunity. Investors may also be layering this news on top of recent execution signals around BRIUMVI’s lifecycle management and commercial momentum.

Details:

TG Therapeutics reported positive topline Phase 1 results for subcutaneous BRIUMVI in myasthenia gravis, highlighting a potentially more convenient administration approach versus IV dosing.

The company also initiated a Phase 2 study evaluating BRIUMVI as maintenance therapy following induction with efgartigimod in adults with myasthenia gravis, a step that can be viewed as program acceleration.

Recent company communications have emphasized BRIUMVI lifecycle efforts (including infusion/dosing improvements) alongside financial updates that included higher BRIUMVI revenue guidance earlier in 2026.

Sources:

TG Therapeutics (press release/IR), GlobeNewswire, TG Therapeutics (Q1 2026 results)

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TGTX Hedge Fund Activity

We have seen 195 institutional investors add shares of $TGTX stock to their portfolio, and 192 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANE STREET GROUP, LLC added 1,071,694 shares (+110.5%) to their portfolio in Q1 2026, for an estimated $35,601,674
CITADEL ADVISORS LLC added 911,852 shares (+90.2%) to their portfolio in Q1 2026, for an estimated $30,291,723
SOLEUS CAPITAL MANAGEMENT, L.P. added 890,007 shares (+28.4%) to their portfolio in Q1 2026, for an estimated $29,566,032
EVENTIDE ASSET MANAGEMENT, LLC removed 716,414 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $23,799,273
WOODLINE PARTNERS LP added 715,500 shares (+inf%) to their portfolio in Q1 2026, for an estimated $23,768,910
DIMENSIONAL FUND ADVISORS LP added 612,068 shares (+129.5%) to their portfolio in Q1 2026, for an estimated $20,332,898
BANK OF AMERICA CORP /DE/ added 610,195 shares (+71.7%) to their portfolio in Q1 2026, for an estimated $20,270,677

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TGTX Price Targets

Multiple analysts have issued price targets for $TGTX recently. We have seen 3 analysts offer price targets for $TGTX in the last 6 months, with a median target of $46.0.

Here are some recent targets:

Emily Bodnar from HC Wainwright & Co. set a target price of $70.0 on 05/27/2026
Brian Cheng from JP Morgan set a target price of $46.0 on 02/02/2026
Corinne Johnson from Goldman Sachs set a target price of $39.0 on 01/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.